AIMS/HYPOTHESIS: Inflammation plays a pathogenic role in the development of accelerated atherosclerosis in diabetes. Soluble CD40 ligand (sCD40L) is enhanced in diabetes; however, the molecular mechanisms linking sCD40L to accelerated atherosclerosis in diabetes are still unclear. We tested the hypothesis that sCD40L may be involved in the vascular complications in diabetes and exerts its effect by triggering inflammatory reactions on mononuclear and endothelial cells (ECs). METHODS: We studied 70 patients, 40 with type 2 and 30 with type 1 diabetes, with a history or physical examination negative for cardiovascular disease, and 40 non-diabetic and 30 healthy subjects, matched with the type 2 and type 1 diabetic patients, respectively. Plasma and serum sCD40L, and plasma soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, E-selectin and monocyte chemo-attractant protein-1 (MCP-1) were measured. Adhesion molecules and MCP-1 release, the ability to repair an injury in ECs, and O2- generation in monocytes were analysed in vitro after stimulation with serum from patients or controls. RESULTS: Type 2 and type 1 diabetic patients had significantly higher sCD40L levels than controls. Furthermore, high sCD40L was associated with in vitro adhesion molecules and MCP-1 release, impaired migration in ECs and enhanced O2- generation in monocytes. Improved metabolic control was associated with a reduction of plasma sCD40L by 37.5% in 12 type 1 diabetic patients. Furthermore, elevated sCD40L in diabetic patients was significantly correlated with HbA1c levels. CONCLUSIONS/ INTERPRETATION: Upregulation of sCD40L as a consequence of persistent hyperglycaemia in diabetic patients results in EC activation and monocyte recruitment to the arterial wall, possibly contributing to accelerated atherosclerosis development in diabetes.
AIMS/HYPOTHESIS: Inflammation plays a pathogenic role in the development of accelerated atherosclerosis in diabetes. Soluble CD40 ligand (sCD40L) is enhanced in diabetes; however, the molecular mechanisms linking sCD40L to accelerated atherosclerosis in diabetes are still unclear. We tested the hypothesis that sCD40L may be involved in the vascular complications in diabetes and exerts its effect by triggering inflammatory reactions on mononuclear and endothelial cells (ECs). METHODS: We studied 70 patients, 40 with type 2 and 30 with type 1 diabetes, with a history or physical examination negative for cardiovascular disease, and 40 non-diabetic and 30 healthy subjects, matched with the type 2 and type 1 diabeticpatients, respectively. Plasma and serum sCD40L, and plasma soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, E-selectin and monocyte chemo-attractant protein-1 (MCP-1) were measured. Adhesion molecules and MCP-1 release, the ability to repair an injury in ECs, and O2- generation in monocytes were analysed in vitro after stimulation with serum from patients or controls. RESULTS: Type 2 and type 1 diabeticpatients had significantly higher sCD40L levels than controls. Furthermore, high sCD40L was associated with in vitro adhesion molecules and MCP-1 release, impaired migration in ECs and enhanced O2- generation in monocytes. Improved metabolic control was associated with a reduction of plasma sCD40L by 37.5% in 12 type 1 diabeticpatients. Furthermore, elevated sCD40L in diabeticpatients was significantly correlated with HbA1c levels. CONCLUSIONS/ INTERPRETATION: Upregulation of sCD40L as a consequence of persistent hyperglycaemia in diabeticpatients results in EC activation and monocyte recruitment to the arterial wall, possibly contributing to accelerated atherosclerosis development in diabetes.
Authors: V Henn; J R Slupsky; M Gräfe; I Anagnostopoulos; R Förster; G Müller-Berghaus; R A Kroczek Journal: Nature Date: 1998-02-05 Impact factor: 49.962
Authors: F Cipollone; M Marini; M Fazia; B Pini; A Iezzi; M Reale; L Paloscia; G Materazzo; E D'Annunzio; P Conti; F Chiarelli; F Cuccurullo; A Mezzetti Journal: Arterioscler Thromb Vasc Biol Date: 2001-03 Impact factor: 8.311
Authors: P Aukrust; F Müller; T Ueland; T Berget; E Aaser; A Brunsvig; N O Solum; K Forfang; S S Frøland; L Gullestad Journal: Circulation Date: 1999-08-10 Impact factor: 29.690
Authors: F Mach; U Schönbeck; G K Sukhova; T Bourcier; J Y Bonnefoy; J S Pober; P Libby Journal: Proc Natl Acad Sci U S A Date: 1997-03-04 Impact factor: 11.205
Authors: Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Marcel J van den Brand; Eric Boersma; Andreas M Zeiher; Maarten L Simoons Journal: N Engl J Med Date: 2003-03-20 Impact factor: 91.245
Authors: Nerea Varo; David Vicent; Peter Libby; Rebecca Nuzzo; Alfonso L Calle-Pascual; María Rosa Bernal; Arturo Fernández-Cruz; Aristidis Veves; Petr Jarolim; Jose Javier Varo; Allison Goldfine; Edward Horton; Uwe Schönbeck Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: N Katakami; H Kaneto; M Matsuhisa; T Miyatsuka; K Sakamoto; D Kawamori; K Yoshiuchi; Y Nakamura; K Kato; K Yamamoto; K Kosugi; M Hori; Y Yamasaki Journal: Diabetologia Date: 2006-05-12 Impact factor: 10.122
Authors: Guohong Li; John M Sanders; Melissa H Bevard; Zhiqi Sun; James W Chumley; Elena V Galkina; Klaus Ley; Ian J Sarembock Journal: Am J Pathol Date: 2008-03-18 Impact factor: 4.307
Authors: F Angelico; C Alessandri; D Ferro; P Pignatelli; M Del Ben; S Fiorello; R Cangemi; L Loffredo; F Violi Journal: Diabetologia Date: 2006-03-29 Impact factor: 10.122
Authors: M Poggi; J Jager; O Paulmyer-Lacroix; F Peiretti; T Gremeaux; M Verdier; M Grino; A Stepanian; S Msika; R Burcelin; D de Prost; J F Tanti; M C Alessi Journal: Diabetologia Date: 2009-01-31 Impact factor: 10.122